Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 637

1.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64.

PMID:
27471869
2.

Multiple Myeloma and Chronic Lymphocytic Leukemia: Commonalities and Differences in Biology and Therapy.

Barlogie B, Gale RP.

Leuk Lymphoma. 1991;5 Suppl 1:27-32. doi: 10.3109/10428199109103375.

PMID:
27463476
3.

CA-125 secreting IgG kappa multiple myeloma.

Boota M, Schinke C, Ledoux S, Alapat D, Khan R, Barlogie B.

Am J Hematol. 2016 Jun 24. doi: 10.1002/ajh.24456. [Epub ahead of print] No abstract available.

PMID:
27340819
4.

The spectrum and clinical impact of epigenetic modifier mutations in myeloma.

Pawlyn C, Kaiser M, Heuck C, Melchor L, Wardell C, Murison A, Chavan S, Johnson DC, Begum DB, Dahir N, Proszek P, Cairns DA, Boyle E, Jones J, Cook G, Drayson MT, Owen R, Gregory WM, Jackson G, Barlogie B, Davies FE, Walker BA, Morgan G.

Clin Cancer Res. 2016 May 27. pii: clincanres.1790.2015. [Epub ahead of print]

PMID:
27235425
5.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.

Cancer Cell. 2016 May 9;29(5):639-52. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.

PMID:
27132469
6.

Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120).

Papanikolaou X, Rosenthal A, Dhodapkar M, Epstein J, Khan R, van Rhee F, Jethava Y, Waheed S, Zangari M, Hoering A, Crowley J, Alapat D, Davies F, Morgan G, Barlogie B.

Blood Cancer J. 2016 Mar 25;6:e410. doi: 10.1038/bcj.2016.19. No abstract available.

7.

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F.

Immunotherapy. 2016;8(3):367-84. doi: 10.2217/imt.15.118. Epub 2016 Feb 17.

PMID:
26888183
8.

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups.

Blood. 2016 Apr 14;127(15):1896-906. doi: 10.1182/blood-2015-08-665679. Epub 2016 Jan 11.

PMID:
26755711
9.

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.

Johnson DC, Weinhold N, Mitchell JS, Chen B, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Försti A, Nickel J, Hoffmann P, Nöethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ.

Nat Commun. 2016 Jan 8;7:10290. doi: 10.1038/ncomms10290.

10.

Genetic factors influencing the risk of multiple myeloma bone disease.

Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens OW, Försti A, Nickel J, Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ.

Leukemia. 2016 Apr;30(4):883-8. doi: 10.1038/leu.2015.342. Epub 2015 Dec 16.

11.

A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.

Erickson SW, Stephens OW, Chavan SS, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13830. [Epub ahead of print] No abstract available.

PMID:
26568154
12.

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.

Bam R, Khan S, Ling W, Randal SS, Li X, Barlogie B, Edmondson R, Yaccoby S.

BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.

13.

Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, Zangari M, Hoering A, Tian E, Davies FE, Barlogie B, Morgan GJ.

Leukemia. 2016 Feb;30(2):423-30. doi: 10.1038/leu.2015.309. Epub 2015 Nov 3.

14.

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

Dhodapkar MV, Sexton R, Das R, Dhodapkar KM, Zhang L, Sundaram R, Soni S, Crowley JJ, Orlowski RZ, Barlogie B.

Blood. 2015 Nov 26;126(22):2475-8. doi: 10.1182/blood-2015-03-632919. Epub 2015 Oct 14.

15.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-51. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30. Review.

16.

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Erickson SW, Stephens OW, Chavan SS, Tian E, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Leukemia. 2015 Dec;29(12):2418-21. doi: 10.1038/leu.2015.238. Epub 2015 Aug 26. No abstract available.

PMID:
26308770
17.

Inhibiting MEK in MAPK pathway-activated myeloma.

Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G.

Leukemia. 2016 Apr;30(4):976-80. doi: 10.1038/leu.2015.208. Epub 2015 Jul 31. No abstract available.

18.

Allelic mutations in noncoding genomic sequences construct novel transcription factor binding sites that promote gene overexpression.

Tian E, Børset M, Sawyer JR, Brede G, Våtsveen TK, Hov H, Waage A, Barlogie B, Shaughnessy JD Jr, Epstein J, Sundan A.

Genes Chromosomes Cancer. 2015 Nov;54(11):692-701. doi: 10.1002/gcc.22280. Epub 2015 Jul 29.

PMID:
26220195
19.

Using a latent class model to refine risk stratification in multiple myeloma.

Qu P, Barlogie B, Crowley J.

Stat Med. 2015 Sep 20;34(21):2971-80. doi: 10.1002/sim.6557. Epub 2015 Jun 17.

PMID:
26084662
20.

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B.

Haematologica. 2015 Sep;100(9):1214-21. doi: 10.3324/haematol.2015.124651. Epub 2015 May 28.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk